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Dementia with Lewy bodies
Diagnosis is only skin deep?
Dementia with Lewy bodies (DLB) is currently diag-
nosed clinically by identifying dementia in combina-
tion with a number of hallmark features: REM sleep
behavior disorder (RBD), prominent visual hallucina-
tions, parkinsonism, and marked fluctuations of cogni-
tion and alertness.1 DLB is often underdiagnosed,
suggesting a role for biomarkers. The main differential
diagnosis of DLB is Alzheimer disease (AD); whereas
both AD and DLB have amyloid deposition, DLB also
has additional a-synuclein deposition (Lewy bodies
and Lewy neurites). So, one way to establish DLB
diagnosis might be to detect the a-synucleinopathy
itself.
A diagnostic biomarker of a-synuclein would be
useful now, but in the future, may become essential.
Currently, all treatments for DLB are symptomatic;
we start treatment when bothersome symptoms
emerge, and adjust based upon clinical response.
For both DLB and AD, we try cholinesterase inhib-
itors and memantine and if possible avoid neurolep-
tics, so incorrect diagnoses may not dramatically
affect treatment. (This applies also to Parkinson dis-
ease [PD]; whether parkinsonism is due to DLB/PD
or other causes, we might still try levodopa.) But
imagine a future in which a-synuclein-based neuro-
protective therapy exists (for example, immunother-
apy against a-synuclein). Now, all patients with
a-synucleinopathy would be eligible for a treatment
that will likely be expensive, inconvenient (e.g.,
monthly IV infusions), and possibly hazardous.
Moreover, unlike symptomatic therapy, there would
be no measurable short-term benefit to guide treat-
ment. So before committing to a lifetime of treat-
ment, patients (and payers) would expect a firm
diagnosis of a-synucleinopathy.
The a-synucleinopathies (DLB, PD) have periph-
eral autonomic nervous system manifestations,2
including constipation, urinary dysfunction, and
orthostatic hypotension. This may be related to
a-synuclein deposition in the gastrointestinal tract,
cardiac sympathetic fibers, and, most notably, the
skin.3 This peripheral localization offers an important
advantage: unlike brain, peripheral tissues like skin
are easily accessible. Skin biopsies require minimal
training, and are relatively safe and noninvasive
(smaller biopsies do not even require a stitch). Prom-
ising studies have documented abnormal a-synuclein
deposition in PD.4 However, techniques are still
being optimized; some studies find clear differences
between patients and controls, whereas others note
a high prevalence of nonspecific staining. Of note,
a recent study documented a-synuclein deposition
in skin biopsies in idiopathic RBD.5 RBD is the
strongest marker of prodromal PD and DLB,6 sug-
gesting that patients with DLB may have similar
abnormalities.
In this issue of Neurology®, Donadio et al.7 report
evidence that skin biopsy can diagnose DLB. The
investigators took punch biopsies from 3 skin sites:
the paravertebral cervical area, proximal thigh, and
distal leg. The proximal biopsies were chosen for a-
synuclein deposition sensitivity, because a-synuclein
is deposited in a rostral–caudal gradient.3 The distal
leg site was chosen to detect subtle neuropathy.
Eighteen patients with DLB were selected (11 with
less certain DLB were excluded). Many had typical
levodopa-responsive parkinsonism, and would pre-
sumably have also met PD criteria (under the new
definition that allows inclusion of patients with
DLB8). Tissues were costained with fluorescent anti-
bodies to identify neuronal tissue and phosphorylated
a-synuclein (p-syn). Patients with DLB were com-
pared to 23 other patients with dementia and 25
controls.
The findings were startling: 100% of patients with
DLB had p-syn deposition in peripheral nervous tis-
sue. By contrast, not a single biopsy in any control
was positive. Even if only one skin sample from
DLB had been taken, sensitivity would still be 95%
for cervical samples (and 86% for proximal thigh,
79% for distal leg). Adrenergic (sympathetic) fibers
were most affected, with deposition also in parasym-
pathetic cholinergic fibers. Those with abnormal
autonomic function tended to have more positive
biopsy samples, but other differences could not be
seen (probably related to ceiling effects).
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On analysis of neuropathy, general autonomic
denervation was seen, observed only in the distal sites.
This denervation occurred without evident neuropa-
thy on nerve conduction studies, consistent with
studies suggesting that patients with PD have mild
small fiber neuropathy.
So, do we have a new diagnostic test for DLB?
There are several caveats and limitations to consider.
A major concern is the unusual nature of the DLB
cohort. This cohort was considerably younger than
average, with a high number of classic DLB features;
every patient had fluctuations, a large majority had
parkinsonism treated with levodopa or dopamine ag-
onists, and 67% had neuroleptic sensitivity. This last
point is surprising (and concerning), considering that
typical neuroleptics are rarely given to patients with
dementia in most specialty practices. The dementia
control group was also atypical, with a mean onset
age of 59 years. Generalizability to more typical pa-
tients with DLB is therefore uncertain. A second
caveat is that nothing in life, including DLB diagno-
sis, is perfect. Seeing 100% sensitivity prompts the
question of how this could have occurred. It appears
that the likeliest explanation is the rigorous selection
procedures to find high clinical diagnostic certainty
(including dopamine transporter scan and iodine-
123-meta-iodobenzylguanidine imaging). However,
this again impairs generalizability; an easily diagnosed
patient will have more positive diagnostic biomarkers,
including skin biopsy. Third, the 100% specificity is
surprising, given that low levels of Lewy body pathol-
ogy are common in clinically diagnosed AD and that
15% of controls at autopsy have incidental CNS
Lewy bodies (some of these should have positive skin
biopsies too, if peripheral deposition is indeed an
early event).9
Given these considerations, the clear priority is to
confirm these results in other more representative co-
horts; these should include possible DLB cases and
more typical late onset AD cases, with follow-up to
see whether p-syn-positive cases evolve to probable
DLB. If the findings are replicated, the implications
are considerable. It is not inconceivable that dementia
physicians will soon be performing skin biopsies as
part of routine diagnostic practice.
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